1. Moving Care Forward in Advanced NSCLC

3. Program Goals

4. Case Study

5. Importance of Histology and Genotyping in NSCLC

7. Many Clinicians are Not Testing for EGFR Mutations in Advanced NSCLC

8. ACCP Guidelines: NSCLC Staging

9. EBUS for Mutation Analysis

10. Sensitizing Mutations in EGFR

11. EGFR Inhibitor Erlotinib: EURTAC

12. EGFR Inhibitor Afatanib: LUX-Lung 3 and LUX-Lung 6 Trials

13. Case Study: Initial Treatment and Progression

14. Mechanisms of Acquired Resistance in EGFR-mutated NSCLC

15. Emerging Agents for Resistance Caused by EGFR T790M Mutation

16. ALK Inhibitor Crizotinib: PROFILE 1014

17. Mechanisms of Acquired Resistance to ALK-Targeted Therapy

18. ALK Inhibitor Ceritinib

19. ALK Inhibitor AP26113 (Brigatinib)

20. ALK Inhibitor Alectinib

21. Abbreviations

22. Abbreviations (cont)

23. Abbreviations (cont)

24. References

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)